| Identification | Back Directory | [Name]
BMS-986308 | [CAS]
2254333-97-4 | [Synonyms]
BMS-986308
3-Pyridinecarbonitrile, 6-[4-[[(3R,5S)-3-(1,3-dihydro-4-methyl-1-oxo-5-isobenzofuranyl)-5-methyl-1-piperazinyl]methyl]-2H-1,2,3-triazol-2-yl]-4-methyl- | [Molecular Formula]
C24H25N7O2 | [MOL File]
2254333-97-4.mol | [Molecular Weight]
443.5 |
| Hazard Information | Back Directory | [Uses]
BMS-986308 is a selective and orally active renal outer medullary potassium (ROMK) channel inhibitor. BMS-986308 is selective for ROMK over hERG. BMS-986308 can be used for heart failure research[1]. | [in vivo]
BMS-986308 (0.01-3 mg/kg; p.o; once) demonstrates efficacy in the volume-loaded rat diuresis model[1]. | Animal Model: | Male Sprague-Dawley rats (age: 8-12 weeks, 270-300 g)[1] | | Dosage: | 0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg and 3 mg/kg | | Administration: | p.o; once (10% v/v DMAC, 40% v/v PEG400, 50% v/v of 30% w/v of HPβCD in 50 mM citrate buffer (pH 4.0)) | | Result: | Led to a robust increase in diuresis. |
| [References]
[1] Jeremy M Richter, et al. Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure. J Med Chem. 2024 Jun 13;67(11):9731-9744. DOI:10.1021/acs.jmedchem.4c00893 |
|
|